News|Articles|March 15, 2020
Monograph Development: Why and When to Participate
Author(s)J. Mark Wiggins, Joseph A. Albanese
This article explores a proactive advocacy approach that a bio/pharmaceutical company may take through participation in the development of new and revised monographs in the various pharmacopoeias.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
How ten23 health is Advancing Patient-Centric Drug Delivery
2
Industry Expert Panel Weighs CNPV Benefits, Risks, and Readiness: Part II
3
FDA, Duke University Planning Epinephrine Access Workshop for December
4
Drug Solutions Podcast: Innovations in Orphan Drugs for Rare Diseases
5
